Related references
Note: Only part of the references are listed.Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation
Xiao Shu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2010)
Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype
Chunyu Zheng et al.
CIRCULATION (2010)
Cardiovascular Death in Dialysis Patients: Lessons We Can Learn from AURORA
Allan D. Sniderman et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
M. Sundaram et al.
JOURNAL OF LIPID RESEARCH (2009)
Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III
Doris T. Chan et al.
JOURNAL OF LIPID RESEARCH (2009)
Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials
Doris T. Chan et al.
ATHEROSCLEROSIS (2008)
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Esther M. M. Ooi et al.
CLINICAL SCIENCE (2008)
Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome
Esther M. M. Ooi et al.
DIABETES CARE (2008)
Plasma apolipoprotein C-III transport in centrally obese men: Associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism
Dick C. Chan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Lipoprotein metabolism in chronic renal insufficiency
Jeffrey M. Saland et al.
PEDIATRIC NEPHROLOGY (2007)
Characterization of apolipoprotein plasma triacylglycerol regulation
Kasuen Wong et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II
P. J. Talmud et al.
DIABETOLOGIA (2006)
Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia
Frank G. Schaap et al.
JOURNAL OF LIPID RESEARCH (2006)
Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma
Minh N. Nguyen et al.
JOURNAL OF LIPID RESEARCH (2006)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
AS Go et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity
JS Cohn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis
FG Schaap et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Potential cardiovascular risk factors in chronic kidney disease:: AGEs, total homocysteine and metabolites, and the C-reactive protein
M Busch et al.
KIDNEY INTERNATIONAL (2004)
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia
JS Cohn et al.
ATHEROSCLEROSIS (2004)
apoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure
E Kimak et al.
RENAL FAILURE (2002)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
